Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy

HPV and Gynecologic Cancer

Prevalence and Risk Factors of Human Papillomavirus Infection in 18-Year-Old Women: Baseline Report of a Prospective Study on Human Papillomavirus Vaccine

J Low Genit Tract Dis.

Igidbashian S, Boveri S, Bottari F, Vidal Urbinati A, Preti E, Casadio C, Landoni F, Sideri M, Sandri MT.

doi: 10.1097/

HPV and Gynecologic Cancer

Human Papillomavirus Vaccine Interventions in the U.S.: A Systematic Review and Meta-analysis

Am J Prev Med.

Rodriguez AM, Do TQN, Goodman M, Schmeler KM, Kaul S, Kuo YF

doi: 10.1016/j.amepre.

HPV and Gynecologic Cancer

Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA): A Trial Protocol

JAMA Netw Open.

Stankiewicz Karita HC, Hauge K, Magaret A, Mao C, Schouten J, Grieco V, Xi LF, Galloway DA, Madeleine MM, Wald A

doi: 10.1001/jamanetworkopen.

HPV and Gynecologic Cancer

Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices

MMWR Morb Mortal Wkly Rep

Meites E, Kempe A, Markowitz LE

doi: 10.15585/mmwr.mm6549a5.

HPV and Gynecologic Cancer

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial

Lancet.

Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A

doi: 10.1016/

HPV and Gynecologic Cancer

Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis

Obstet Gynecol.

Lichter K, Krause D, Xu J, Tsai SHL, Hage C, Weston E, Eke A, Levinson K

doi: 10.1097/AOG.0000000000003833.

HPV and Gynecologic Cancer

Effects of Educational Interventions on Human Papillomavirus Vaccine Acceptability: A Randomized Controlled Trial

Obstet Gynecol.

Cory L, Cha B, Ellenberg S, Bogner HR, Hwang WT, Smith JS, Haggerty A, Morgan M, Burger R, Chu C, Ko EM

doi: 10.1097/AOG.0000000000003379.

HPV and Gynecologic Cancer

Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study

Lancet Glob Health.

Abbas KM, van Zandvoort K, Brisson M, Jit M

doi: 10.1016/S2214-109X(20)30022-X.

HPV and Gynecologic Cancer

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age

Hum Vaccin Immunother.

Moreira ED, Giuliano AR, de Hoon J, Iversen OE, Joura EA, Restrepo J, Van Damme P, Vandermeulen C, Ellison MC, Krick A, Shields C, Heiles B, Luxembourg A

doi: 10.1080/21645515.

Related content

Prevalence and Risk Factors of Human Papillomavirus Infection in 18-Year-Old Women: Baseline Report of a Prospective Study on Human Papillomavirus Vaccine

Human Papillomavirus Vaccine Interventions in the U.S.: A Systematic Review and Meta-analysis

Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA): A Trial Protocol

Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial

Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis

Effects of Educational Interventions on Human Papillomavirus Vaccine Acceptability: A Randomized Controlled Trial

Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age